expect another solid growth qtr when they report next month...i don't see the stock should see 200 plus by end of year. their drug is the only game in town.
seen it way too many times
alxn should not have been sold off in the first place...it is a $200+ stock.
going lower as people start to get the news and digest what it all means
stock should drop further when trading resumes
for news release
and they don't know why? or perhaps worry about price tag of drug? the catalyst would be approval by eu and fda.